- Myriad Genetics' ( NASDAQ: MYGN ) GeneSight Psychotropic test led to significant improvements in depression remission rates, according to a new study .
- The test can help determine how an individual may metabolize or respond to certain psychiatric medications. This can help physicians determine the best drug for a patient without going through the trial-and-error process common following many mental health diagnoses.
- Results from a study of nearly 2K U.S. veterans showed that after 24 weeks, the group that received pharmacogenomic information at the outset had a 28% greater likelihood of remission from major depressive disorder symptoms.
- For a secondary co-endpoint, those in the usual care group were ~2x more likely to be given drugs with significant predicted gene-drug interactions compared to the pharmacogenomic guided group in the first 30 days after randomization.
- The study was conducted and funded by the Veterans Administration. Results were published in JAMA .
- Seeking Alpha's Quant Rating views Myriad ( MYGN ) as a buy with an A+ for growth .
For further details see:
Myriad Genetics touts study results of GeneSight test on depression remission rates